Mark Pollack to Cyclohexanols
This is a "connection" page, showing publications Mark Pollack has written about Cyclohexanols.
Connection Strength
2.063
-
Response to Silberman. Am J Psychiatry. 2014 Jul; 171(7):795-6.
Score: 0.499
-
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.
Score: 0.482
-
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
Score: 0.307
-
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007; 24(1):1-14.
Score: 0.297
-
Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003 Jun; 23(3):250-9.
Score: 0.231
-
Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996; 32(4):667-70.
Score: 0.138
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
Score: 0.063
-
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000 Jun; 157(6):968-74.
Score: 0.047